Display options
Cite
Bergman H, Henschke N, Hungerford D, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2021;11:CD008521doi: 10.1002/14651858.CD008521.pub6.
Bergman, H., Henschke, N., Hungerford, D., Pitan, F., Ndwandwe, D., Cunliffe, N., & Soares-Weiser, K. (2021). Vaccines for preventing rotavirus diarrhoea: vaccines in use. The Cochrane database of systematic reviews, 11CD008521. https://doi.org/10.1002/14651858.CD008521.pub6
Bergman, Hanna, et al. "Vaccines for preventing rotavirus diarrhoea: vaccines in use." The Cochrane database of systematic reviews vol. 11 (2021): CD008521. doi: https://doi.org/10.1002/14651858.CD008521.pub6
Bergman H, Henschke N, Hungerford D, Pitan F, Ndwandwe D, Cunliffe N, Soares-Weiser K. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2021 Nov 17;11:CD008521. doi: 10.1002/14651858.CD008521.pub6. PMID: 34788488; PMCID: PMC8597890.
Copy Download .nbib Format: NLM
Share it on

Cochrane Database Syst Rev. 2021 Nov 17;11:CD008521. doi: 10.1002/14651858.CD008521.pub6.

Vaccines for preventing rotavirus diarrhoea: vaccines in use.

The Cochrane database of systematic reviews

Hanna Bergman, Nicholas Henschke, Daniel Hungerford, Femi Pitan, Duduzile Ndwandwe, Nigel Cunliffe, Karla Soares-Weiser

Affiliations

  1. Cochrane Response, Cochrane, London, UK.
  2. Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  3. NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, UK.
  4. Chevron Corporation, Lagos, Nigeria.
  5. Cochrane South Africa, South African Medical Research Council , Cape Town, South Africa.
  6. Editorial & Methods Department, Cochrane, London, UK.

PMID: 34788488 PMCID: PMC8597890 DOI: 10.1002/14651858.CD008521.pub6

Abstract

BACKGROUND: Rotavirus is a common cause of diarrhoea, diarrhoea-related hospital admissions, and diarrhoea-related deaths worldwide. Rotavirus vaccines prequalified by the World Health Organization (WHO) include Rotarix (GlaxoSmithKline), RotaTeq (Merck), and, more recently, Rotasiil (Serum Institute of India Ltd.), and Rotavac (Bharat Biotech Ltd.).

OBJECTIVES: To evaluate rotavirus vaccines prequalified by the WHO for their efficacy and safety in children.

SEARCH METHODS: On 30 November 2020, we searched PubMed, the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (published in the Cochrane Library), Embase, LILACS, Science Citation Index Expanded, Social Sciences Citation Index, Conference Proceedings Citation Index-Science, Conference Proceedings Citation Index-Social Science & Humanities. We also searched the WHO ICTRP, ClinicalTrials.gov, clinical trial reports from manufacturers' websites, and reference lists of included studies, and relevant systematic reviews.

SELECTION CRITERIA: We selected randomized controlled trials (RCTs) conducted in children that compared rotavirus vaccines prequalified for use by the WHO with either placebo or no intervention.

DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial eligibility and assessed risk of bias. One author extracted data and a second author cross-checked them. We combined dichotomous data using the risk ratio (RR) and 95% confidence interval (CI). We stratified the analyses by under-five country mortality rate and used GRADE to evaluate evidence certainty.

MAIN RESULTS: Sixty trials met the inclusion criteria and enrolled a total of 228,233 participants. Thirty-six trials (119,114 participants) assessed Rotarix, 15 trials RotaTeq (88,934 participants), five trials Rotasiil (11,753 participants), and four trials Rotavac (8432 participants). Rotarix Infants vaccinated and followed up for the first year of life In low-mortality countries, Rotarix prevented 93% of severe rotavirus diarrhoea cases (14,976 participants, 4 trials; high-certainty evidence), and 52% of severe all-cause diarrhoea cases (3874 participants, 1 trial; moderate-certainty evidence).  In medium-mortality countries, Rotarix prevented 79% of severe rotavirus diarrhoea cases (31,671 participants, 4 trials; high-certainty evidence), and 36% of severe all-cause diarrhoea cases (26,479 participants, 2 trials; high-certainty evidence).  In high-mortality countries, Rotarix prevented 58% of severe rotavirus diarrhoea cases (15,882 participants, 4 trials; high-certainty evidence), and 27% of severe all-cause diarrhoea cases (5639 participants, 2 trials; high-certainty evidence). Children vaccinated and followed up for two years In low-mortality countries, Rotarix prevented 90% of severe rotavirus diarrhoea cases (18,145 participants, 6 trials; high-certainty evidence), and 51% of severe all-cause diarrhoea episodes (6269 participants, 2 trials; moderate-certainty evidence).   In medium-mortality countries, Rotarix prevented 77% of severe rotavirus diarrhoea cases (28,834 participants, 3 trials; high-certainty evidence), and 26% of severe all-cause diarrhoea cases (23,317 participants, 2 trials; moderate-certainty evidence).  In high-mortality countries, Rotarix prevented 35% of severe rotavirus diarrhoea cases (13,768 participants, 2 trials; moderate-certainty evidence), and 17% of severe all-cause diarrhoea cases (2764 participants, 1 trial; high-certainty evidence). RotaTeq Infants vaccinated and followed up for the first year of life In low-mortality countries, RotaTeq prevented 97% of severe rotavirus diarrhoea cases (5442 participants, 2 trials; high-certainty evidence).  In medium-mortality countries, RotaTeq prevented 79% of severe rotavirus diarrhoea cases (3863 participants, 1 trial; low-certainty evidence).  In high-mortality countries, RotaTeq prevented 57% of severe rotavirus diarrhoea cases (6775 participants, 2 trials; high-certainty evidence), but there is probably little or no difference between vaccine and placebo for severe all-cause diarrhoea (1 trial, 4085 participants; moderate-certainty evidence).  Children vaccinated and followed up for two years In low-mortality countries, RotaTeq prevented 96% of severe rotavirus diarrhoea cases (5442 participants, 2 trials; high-certainty evidence).  In medium-mortality countries, RotaTeq prevented 79% of severe rotavirus diarrhoea cases (3863 participants, 1 trial; low-certainty evidence).  In high-mortality countries, RotaTeq prevented 44% of severe rotavirus diarrhoea cases (6744 participants, 2 trials; high-certainty evidence), and 15% of severe all-cause diarrhoea cases (5977 participants, 2 trials; high-certainty evidence).  We did not identify RotaTeq studies reporting on severe all-cause diarrhoea in low- or medium-mortality countries. Rotasiil Rotasiil has not been assessed in any RCT in countries with low or medium child mortality. Infants vaccinated and followed up for the first year of life In high-mortality countries, Rotasiil prevented 48% of severe rotavirus diarrhoea cases (11,008 participants, 2 trials; high-certainty evidence), and resulted in little to no difference in severe all-cause diarrhoea cases (11,008 participants, 2 trials; high-certainty evidence). Children vaccinated and followed up for two years In high-mortality countries, Rotasiil prevented 44% of severe rotavirus diarrhoea cases (11,008 participants, 2 trials; high-certainty evidence), and resulted in little to no difference in severe all-cause diarrhoea cases (11,008 participants, 2 trials; high-certainty evidence). Rotavac Rotavac has not been assessed in any RCT in countries with low or medium child mortality.  Infants vaccinated and followed up for the first year of life In high-mortality countries, Rotavac prevented 57% of severe rotavirus diarrhoea cases (6799 participants, 1 trial; moderate-certainty evidence), and 16% of severe all-cause diarrhoea cases (6799 participants, 1 trial; moderate-certainty evidence). Children vaccinated and followed up for two years In high-mortality countries, Rotavac prevented 54% of severe rotavirus diarrhoea cases (6541 participants, 1 trial; moderate-certainty evidence); no Rotavac studies have reported on severe all-cause diarrhoea at two-years follow-up. Safety No increased risk of serious adverse events (SAEs) was detected with Rotarix (103,714 participants, 31 trials; high-certainty evidence), RotaTeq (82,502 participants, 14 trials; moderate to high-certainty evidence), Rotasiil (11,646 participants, 3 trials; high-certainty evidence), or Rotavac (8210 participants, 3 trials; moderate-certainty evidence). Deaths were infrequent and the analysis had insufficient evidence to show an effect on all-cause mortality. Intussusception was rare.  AUTHORS' CONCLUSIONS: Rotarix, RotaTeq, Rotasiil, and Rotavac prevent episodes of rotavirus diarrhoea. The relative effect estimate is smaller in high-mortality than in low-mortality countries, but more episodes are prevented in high-mortality settings as the baseline risk is higher. In high-mortality countries some results suggest lower efficacy in the second year. We found no increased risk of serious adverse events, including intussusception, from any of the prequalified rotavirus vaccines.

Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

References

  1. Vaccine. 2012 Apr 27;30 Suppl 1:A36-43 - PubMed
  2. Hum Vaccin. 2010 Mar 26;6(3): - PubMed
  3. Hum Vaccin Immunother. 2021 Apr 3;17(4):1223-1234 - PubMed
  4. Eur J Pediatr. 2010 Nov;169(11):1379-86 - PubMed
  5. Cochrane Database Syst Rev. 2010 May 12;(5):CD008521 - PubMed
  6. J Infect Dis. 2014 Dec 1;210(11):1772-9 - PubMed
  7. J Infect Dis. 2010 Sep 1;202 Suppl:S93-100 - PubMed
  8. Lancet. 2010 Aug 21;376(9741):615-23 - PubMed
  9. BMC Pediatr. 2017 Jan 13;17(1):14 - PubMed
  10. N Engl J Med. 2006 Jan 5;354(1):23-33 - PubMed
  11. Ann Acad Med Singap. 2006 Jan;35(1):38-44 - PubMed
  12. Ann Acad Med Singap. 2008 Jul;37(7):546-53 - PubMed
  13. N Engl J Med. 2018 Feb 22;378(8):719-730 - PubMed
  14. N Engl J Med. 2010 Jan 28;362(4):289-98 - PubMed
  15. Lancet. 2007 Nov 24;370(9601):1757-63 - PubMed
  16. Lancet. 2014 Jun 21;383(9935):2136-43 - PubMed
  17. Vaccine. 2019 May 1;37(19):2554-2560 - PubMed
  18. Vaccine. 2014 Aug 11;32 Suppl 1:A134-9 - PubMed
  19. Pediatr Infect Dis J. 2009 Mar;28(3):177-81 - PubMed
  20. Vaccine. 2014 Aug 11;32 Suppl 1:A110-6 - PubMed
  21. Cochrane Database Syst Rev. 2012 Nov 14;11:CD008521 - PubMed
  22. Vaccine. 2014 Aug 11;32 Suppl 1:A117-23 - PubMed
  23. J Pediatr. 2006 Jul;149(1):143 - PubMed
  24. Vaccine. 2010 Sep 7;28(39):6542-8 - PubMed
  25. MMWR Recomm Rep. 2006 Aug 11;55(RR-12):1-13 - PubMed
  26. Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19;370(1671): - PubMed
  27. Pediatrics. 2008 Nov;122(5):e1062-6 - PubMed
  28. Vaccine. 2015 Jan 1;33(1):52-61 - PubMed
  29. Heliyon. 2017 May 16;3(5):e00302 - PubMed
  30. Hum Vaccin. 2009 Jun;5(6):414-9 - PubMed
  31. J Infect Dis. 2013 Aug 1;208(3):423-31 - PubMed
  32. BMC Pediatr. 2010 Jun 11;10:42 - PubMed
  33. N Engl J Med. 2010 Jan 28;362(4):299-305 - PubMed
  34. Lancet. 2008 Apr 5;371(9619):1181-9 - PubMed
  35. Pediatr Infect Dis J. 2004 Oct;23(10):937-43 - PubMed
  36. Hum Vaccin Immunother. 2013 Aug;9(8):1638-42 - PubMed
  37. J Infect Dis. 2009 Aug 1;200(3):421-9 - PubMed
  38. Scand J Infect Dis. 1990;22(3):259-67 - PubMed
  39. J Infect Dis. 2007 Aug 15;196(4):537-40 - PubMed
  40. Rev Gastroenterol Peru. 2012 Jan-Mar;32(1):11-5 - PubMed
  41. Pediatr Infect Dis J. 2017 Apr;36(4):417-422 - PubMed
  42. Ann Acad Med Singap. 2016 Feb;45(2):44-50 - PubMed
  43. AIDS. 2017 Jan 2;31(1):49-59 - PubMed
  44. Vaccine. 2006 May 1;24(18):3784-5 - PubMed
  45. Nat Rev Dis Primers. 2017 Nov 09;3:17083 - PubMed
  46. Lancet. 1997 Nov 22;350(9090):1538-41 - PubMed
  47. Sci Transl Med. 2019 Aug 14;11(505): - PubMed
  48. Lancet Infect Dis. 2015 Dec;15(12):1389-97 - PubMed
  49. Pediatr Infect Dis J. 2016 Sep;35(9):992-8 - PubMed
  50. Hum Vaccin Immunother. 2016 Mar 3;12(3):785-93 - PubMed
  51. PLoS One. 2015 Dec 16;10(12):e0145568 - PubMed
  52. PLoS Med. 2017 Apr 18;14(4):e1002282 - PubMed
  53. Cochrane Database Syst Rev. 2019 Mar 25;3:CD008521 - PubMed
  54. Pediatr Infect Dis J. 2007 Dec;26(12):1099-104 - PubMed
  55. J Formos Med Assoc. 2009 Apr;108(4):280-5 - PubMed
  56. J Infect. 2016 Jul 5;72 Suppl:S13-22 - PubMed
  57. Vaccine. 2012 Apr 27;30 Suppl 1:A24-9 - PubMed
  58. Sci Rep. 2015 Oct 06;5:14658 - PubMed
  59. N Engl J Med. 2017 Jul 20;377(3):302 - PubMed
  60. Viral Immunol. 2007 Summer;20(2):300-11 - PubMed
  61. BMC Med. 2018 Jan 29;16(1):10 - PubMed
  62. J Infect Dis. 2016 Jun 1;213(11):1678-85 - PubMed
  63. Vaccine. 2021 Mar 5;39(10):1534-1543 - PubMed
  64. Pediatrics. 2007 Aug;120(2):e253-61 - PubMed
  65. Vaccine. 2012 Apr 27;30 Suppl 1:A101-5 - PubMed
  66. Cochrane Database Syst Rev. 2004;(1):CD002848 - PubMed
  67. Lancet Glob Health. 2018 Sep;6(9):e1036-e1044 - PubMed
  68. Pediatr Infect Dis J. 2012 May;31(5):509-13 - PubMed
  69. J Pediatr (Rio J). 2007 May-Jun;83(3):217-24 - PubMed
  70. Vaccine. 2012 Apr 27;30 Suppl 1:A61-70 - PubMed
  71. Hum Vaccin Immunother. 2017 Aug 3;13(8):1916-1920 - PubMed
  72. Pediatrics. 2010 Dec;126(6):e1499-506 - PubMed
  73. J Infect Dis. 2017 Mar 15;215(6):928-932 - PubMed
  74. Vaccine. 2012 Apr 27;30 Suppl 1:A44-51 - PubMed
  75. Vaccine. 2009 Feb 25;27(9):1333-9 - PubMed
  76. Vaccine. 2017 Jun 16;35(28):3575-3581 - PubMed
  77. Pediatr Infect Dis J. 2005 Jun;24(6):481-8 - PubMed
  78. Pediatr Infect Dis J. 2010 Mar;29(3):263-5 - PubMed
  79. J Infect Dis. 2020 May 04;: - PubMed
  80. Vaccine. 2019 Jul 18;37(31):4407-4413 - PubMed
  81. Wkly Epidemiol Rec. 2012 May 25;87(21):201-16 - PubMed
  82. Pediatr Infect Dis J. 2008 Oct;27(10):874-80 - PubMed
  83. N Engl J Med. 2006 Jan 5;354(1):11-22 - PubMed
  84. Vaccine. 2015 Jun 9;33(25):2939-43 - PubMed
  85. Vaccine. 1998 Feb;16(4):381-7 - PubMed
  86. Vaccine. 2009 Oct 9;27(43):5936-41 - PubMed
  87. Hum Vaccin Immunother. 2014;10(1):19-24 - PubMed
  88. Vaccine. 2006 May 1;24(18):3782-3 - PubMed
  89. Hum Vaccin Immunother. 2017 May 4;13(5):1136-1140 - PubMed
  90. Vaccine. 2018 Jun 14;36(25):3674-3680 - PubMed
  91. J Infect Dis. 2018 Jul 13;218(4):606-613 - PubMed
  92. Vaccine. 2012 Apr 27;30 Suppl 1:A86-93 - PubMed
  93. Clin Infect Dis. 2018 Jul 2;67(2):186-192 - PubMed
  94. J Infect Dis. 2016 Jun 1;213(11):1673-5 - PubMed
  95. Pediatr Infect Dis J. 2015 Jun;34(6):635-43 - PubMed
  96. N Engl J Med. 2018 Apr 19;378(16):1521-1528 - PubMed
  97. Hum Vaccin Immunother. 2012 Jun;8(6):806-12 - PubMed
  98. J Infect Dis. 2016 Jun 1;213(11):1686-93 - PubMed
  99. Vaccine. 2018 Jan 4;36(2):273-279 - PubMed
  100. Front Immunol. 2018 Jan 19;8:2002 - PubMed
  101. Lancet Infect Dis. 2020 Jul;20(7):851-863 - PubMed
  102. MMWR Recomm Rep. 1999 Mar 19;48(RR-2):1-20 - PubMed
  103. Vaccine. 2012 Apr 27;30 Suppl 1:A52-60 - PubMed
  104. J Infect Dis. 2005 Sep 1;192 Suppl 1:S36-43 - PubMed
  105. Vaccine. 2006 May 29;24(22):4821-9 - PubMed
  106. JAMA. 2012 Feb 8;307(6):598-604 - PubMed
  107. Vaccine. 2018 Jan 4;36(2):264-272 - PubMed
  108. N Engl J Med. 2014 Feb 6;370(6):513-9 - PubMed
  109. N Engl J Med. 2011 Dec 1;365(22):2139 - PubMed
  110. Vaccine. 2018 Dec 18;36(52):7943-7949 - PubMed
  111. Hum Vaccin Immunother. 2017 Aug 3;13(8):1908-1915 - PubMed
  112. Pediatr Infect Dis J. 2012 May;31(5):487-93 - PubMed
  113. Pediatr Infect Dis J. 2005 Sep;24(9):807-16 - PubMed
  114. J Infect Dis. 2018 Mar 5;217(6):861-868 - PubMed
  115. N Engl J Med. 2017 Mar 23;376(12):1121-1130 - PubMed
  116. Hum Vaccin Immunother. 2013 Aug;9(8):1626-33 - PubMed
  117. Vaccine. 2020 Feb 24;38(9):2190-2197 - PubMed
  118. PLoS Med. 2012;9(10):e1001330 - PubMed
  119. Vaccine. 2019 Mar 22;37(13):1836-1843 - PubMed
  120. Vaccine. 2015 Feb 18;33(8):1017-20 - PubMed
  121. Vaccine. 2006 Jul 26;24(31-32):5817-23 - PubMed
  122. Vaccine. 2020 Oct 27;38(46):7393-7400 - PubMed
  123. N Engl J Med. 2001 Feb 22;344(8):564-72 - PubMed
  124. Pediatr Infect Dis J. 2019 May;38(5):539-541 - PubMed
  125. Vaccine. 2012 Apr 27;30 Suppl 1:A122-30 - PubMed
  126. J Infect Dis. 2020 Oct 13;222(10):1731-1739 - PubMed
  127. Pediatr Infect Dis J. 2003 Oct;22(10):914-20 - PubMed
  128. Pediatr Infect Dis J. 2010 Oct;29(10):957-63 - PubMed
  129. BMC Infect Dis. 2017 Aug 15;17(1):569 - PubMed
  130. Pediatr Infect Dis J. 2007 Mar;26(3):221-7 - PubMed
  131. PLoS Med. 2011 Apr;8(4):e1001024 - PubMed
  132. Vaccine. 2011 Nov 28;29(51):9508-13 - PubMed
  133. Vaccine. 2004 Jul 29;22(21-22):2836-42 - PubMed
  134. Vaccine. 2012 Apr 27;30 Suppl 1:A79-85 - PubMed
  135. BMC Biol. 2010 Oct 04;8:129 - PubMed
  136. Pediatrics. 2016 Feb;137(2):e20152603 - PubMed
  137. Trials. 2014 Jun 28;15:256 - PubMed
  138. J Infect Dis. 2004 Jun 15;189(12):2290-3 - PubMed
  139. Pediatrics. 2007 Jan;119(1):11-8 - PubMed
  140. Am J Trop Med Hyg. 2015 Apr;92(4):744-51 - PubMed
  141. Hum Vaccin. 2011 Jan 1;7(1):74-80 - PubMed
  142. Int J Infect Dis. 2007 Nov;11 Suppl 2:S29-35 - PubMed
  143. Clin Infect Dis. 2006 Aug 1;43(3):312-4 - PubMed
  144. Future Microbiol. 2018 Jan;13:97-118 - PubMed
  145. Vaccine. 2012 Apr 27;30 Suppl 1:A71-8 - PubMed
  146. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008521 - PubMed
  147. Hum Vaccin Immunother. 2014;10(6):1436-48 - PubMed
  148. Vaccine. 2016 Jul 12;34(32):3684-9 - PubMed
  149. Hum Vaccin Immunother. 2019;15(4):800-808 - PubMed
  150. N Engl J Med. 2014 Feb 6;370(6):503-12 - PubMed
  151. Vaccine. 2009 Dec 11;28(2):345-51 - PubMed
  152. N Engl J Med. 2020 Nov 12;383(20):1932-1940 - PubMed
  153. J Infect Dis. 1996 Sep;174 Suppl 1:S73-80 - PubMed
  154. Lancet Infect Dis. 2019 Jul;19(7):717-727 - PubMed
  155. BMC Infect Dis. 2012 Sep 13;12:213 - PubMed
  156. J Infect Dis. 2006 Dec 15;194(12):1729-36 - PubMed
  157. J Infect Dis. 2021 Oct 13;224(7):1147-1151 - PubMed
  158. Pediatr Infect Dis J. 2017 Jan;36(1):72-78 - PubMed
  159. Wkly Epidemiol Rec. 2009 Jun 5;84(23):220-36 - PubMed
  160. Hum Vaccin Immunother. 2020 Mar 3;16(3):693-702 - PubMed
  161. Vaccine. 2011 Mar 3;29(11):2079-84 - PubMed
  162. Int J Infect Dis. 2007 Nov;11 Suppl 2:S36-42 - PubMed
  163. Vaccine. 2012 Apr 27;30 Suppl 1:A114-21 - PubMed
  164. Lancet. 1999 Jul 24;354(9175):287-90 - PubMed
  165. Vaccine. 2011 Apr 5;29(16):3061-6 - PubMed
  166. Vaccine. 2013 Apr 26;31(18):2253-9 - PubMed
  167. Clin Infect Dis. 2016 Jan 15;62(2):150-6 - PubMed
  168. Vaccine. 2014 Aug 11;32 Suppl 1:A129-33 - PubMed
  169. Lancet. 2010 Aug 21;376(9741):606-14 - PubMed
  170. Pediatr Infect Dis J. 2004 Oct;23(10 Suppl):S179-82 - PubMed
  171. Vaccine. 2011 Aug 26;29(37):6335-41 - PubMed
  172. Lancet Infect Dis. 2017 Aug;17(8):843-853 - PubMed
  173. Vaccine. 2012 Apr 27;30 Suppl 1:A94-100 - PubMed
  174. Pediatr Infect Dis J. 2011 Jun;30(6):e103-8 - PubMed
  175. Hum Vaccin Immunother. 2016 Oct 2;12(10):2580-2589 - PubMed
  176. Clin Infect Dis. 2017 Sep 1;65(5):840-850 - PubMed
  177. Lancet Glob Health. 2020 Sep;8(9):e1195-e1202 - PubMed
  178. J Pediatr. 2004 Feb;144(2):184-90 - PubMed
  179. J Infect Dis. 2018 Apr 11;217(9):1399-1407 - PubMed
  180. BMC Public Health. 2011 Apr 13;11 Suppl 3:S16 - PubMed
  181. Vaccine. 2017 Oct 27;35(45):6228-6237 - PubMed
  182. Pediatr Infect Dis J. 2008 Feb;27(2):177-8 - PubMed
  183. Pediatr Infect Dis J. 2013 Apr;32(4):e134-47 - PubMed
  184. Pediatr Infect Dis J. 2016 Oct;35(10):1137-9 - PubMed
  185. N Engl J Med. 2011 Jul 28;365(4):337-46 - PubMed
  186. J Infect Dis. 2005 Sep 1;192 Suppl 1:S6-S16 - PubMed
  187. Vaccine. 2017 Oct 13;35(43):5897-5904 - PubMed
  188. Vaccine. 2012 Jun 22;30(30):4552-7 - PubMed
  189. Vaccine. 2012 Apr 27;30 Suppl 1:A106-13 - PubMed
  190. J Infect Dis. 2017 Mar 1;215(5):786-789 - PubMed
  191. Clin Infect Dis. 2016 Sep 1;63(5):634-41 - PubMed
  192. Clin Infect Dis. 2013 Nov;57(10):1427-34 - PubMed
  193. Lancet Infect Dis. 2012 Feb;12(2):136-41 - PubMed
  194. Vaccine. 2020 Dec 3;38(51):8161-8166 - PubMed
  195. Pediatr Infect Dis J. 2012 Feb;31(2):184-8 - PubMed
  196. Science. 2006 May 12;312(5775):851-2 - PubMed
  197. Vaccine. 2018 Sep 5;36(37):5519-5523 - PubMed
  198. J Pediatr Gastroenterol Nutr. 2013 Jun;56(6):635-40 - PubMed
  199. Indian Pediatr. 2015 Oct;52(10):906 - PubMed
  200. Vaccine. 2011 Mar 3;29(11):2029-36 - PubMed
  201. Mem Inst Oswaldo Cruz. 2012 Nov;107(7):846-53 - PubMed
  202. Clin Vaccine Immunol. 2011 May;18(5):878-84 - PubMed
  203. Pediatr Infect Dis J. 2011 Feb;30(2):125-30 - PubMed
  204. N Engl J Med. 2011 Jun 16;364(24):2283-92 - PubMed
  205. JAMA Netw Open. 2019 Oct 2;2(10):e1912458 - PubMed
  206. Vaccine. 2006 May 1;24(18):3780-1 - PubMed
  207. Hum Vaccin Immunother. 2014;10(1):11-8 - PubMed
  208. Vaccine. 2014 Aug 11;32 Suppl 1:A104-9 - PubMed
  209. Pediatr Infect Dis J. 2008 Jul;27(7):656-8 - PubMed
  210. Vaccine. 2019 Nov 20;37(49):7233-7239 - PubMed
  211. J Infect Dis. 2002 Nov 15;186(10):1487-9 - PubMed
  212. Vaccine. 2014 Aug 11;32 Suppl 1:A124-8 - PubMed
  213. N Engl J Med. 1996 Oct 3;335(14):1022-8 - PubMed
  214. Vaccine. 2010 Jul 19;28(32):5272-9 - PubMed
  215. J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):82-85 - PubMed
  216. Clin Infect Dis. 2020 Apr 10;70(8):1606-1612 - PubMed
  217. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed

Publication Types

Grant support